Morepen Laboratories Releases Monitoring Agency Report for Q2FY27 QIP Proceeds
Morepen Laboratories Ltd · Others (Uncategorized) · 27 Oct 2026, 8:48 pm
Morepen Laboratories Releases Monitoring Agency Report for Q2FY27 QIP Proceeds CARE Ratings reported no material deviation in Morepen Laboratories' ₹200.00 crore QIP proceeds utilization for the quarter ended 30th Sep'26. Total net proceeds of ₹189.08 crore saw cumulative deployment of ₹181.10 crore, with ₹1.12 crore utilized in Q2FY27 for modernization and expansion of Baddi units. Working capital funding of ₹66.29 crore stands fully utilized. Unutilized proceeds of ₹7.98 crore remain invested in debt mutual funds and bank balances. Capex completion timelines were extended to 31st Mar'27, with the monitoring agency flagging potential cost overrun risks.
Original exchange filing (PDF)
More announcements from Morepen Laboratories Ltd
- Update on Credit Rating · 14 Nov 2026
- Please find attached the Press Release · 09 Nov 2026
- Change in Senior Management Personnel on account of resignation · 31 Oct 2026
- Change in Designation of Senior Management Personnel of the Company · 28 Oct 2026
- Please find attached the Investor Presentation for Q2 & H1 FY 27 Financial Results · 27 Oct 2026
- Please find attached the press release · 27 Oct 2026
- Please find attached the Q2 & H1 FY 27 Financial Results · 27 Oct 2026
- Please find attached the Q2 & H1 FY27 Financial Results along with Limited Review Report · 27 Oct 2026
